Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 19;3(1):e000098.
doi: 10.1136/lupus-2015-000098. eCollection 2016.

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus

L Carli  1 , C Tani  2 , V Spera  2 , R Vagelli  2 , S Vagnani  2 , M Mazzantini  2 , O Di Munno  2 , M Mosca  2
Affiliations

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus

L Carli et al. Lupus Sci Med. .

Abstract

Osteoporosis (OP) and fragility fractures (FFx) are a known comorbidity in patients with systemic lupus erythematosus (SLE). This work aimed at evaluating (1) the prevalence of OP and FFx in a cohort of SLE and (2) the risk factors associated with both OP and FFx. The following data were collected from clinical charts: age, sex, menopausal status (MP), body mass index, smoking habits, disease duration, daily dose and cumulative glucocorticoids (GCs), type of organ involvement, comorbidities and medications. Data on bone metabolism, calcium and vitamin D supplementation and treatment with bisphosphonates, teriparatide or denosumab were collected, together with bone mineral density (BMD) values (measured by dual-energy X-ray absorptiometry (DXA)) and history of FFx (occurred after the onset of SLE and unrelated to trauma). OP and reduced BMD were defined according to the WHO. 186 patients were included (women 175, men 11; mean age 46.4±13 years, mean disease duration 14.9±9 years). At their last visit, 97 patients (52.2%) had a reduced BMD and 52 (27.9%) had OP. 22 patients (11.8%), all women, had at least one FFx; six patients (27.3%) were pre-menopausal. On univariate analysis, age, cumulative dose of GC, MP, therapy with antiepileptics and chronic renal failure (CRF) were correlated with OP (p<0.03); age, total amount of GC, MP, CRF, anticoagulants (AC) and antiepileptic therapy were correlated with FFx (p<0.05). The multivariate logistic model confirmed a direct association of OP and age, MP and antiepileptic therapy (p≤0.01) and of FFx and age, chronic therapy with AC and antiepileptics (p<0.03). In conclusion, low BMD is frequently observed in SLE, and FFx are observed also in premenopausal patients. Together with traditional risk factors (age, MP and GC), CRF and chronic treatments with AC or antiepileptics seem to be associated with a higher risk profile for OP and FFx occurrence.

Keywords: Fragility fractures; Osteoporosis; Premenopausal women; Risk factors; Systemic Lupus Erythematosus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of bone mineral density (BMD) values in our cohort. OP, osteoporosis.
See this image and copyright information in PMC

References

    1. Di Munno O, Mazzantini M, Delle Sedie A et al. Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus 2004;13:724–30. doi:10.1191/0961203303lu1097oa - DOI - PubMed
    1. Ramsey-Goldman R, Dunn JE, Huang CF et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999;42:882–90. doi:10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C - DOI - PubMed
    1. Grossman JM, Gordon R, Ranganath VK et al. American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515–26. doi:10.1002/acr.20295 - DOI - PubMed
    1. Di Munno O, Delle Sedie A. Prevention and treatment of glucocorticoid-induced osteoporosis in International and italian scenarios. Reumatismo 2011;63:67–79. doi:10.4081/reumatismo.2011.67 - DOI - PubMed
    1. Rodrigues Pereira RM, Freire de Carvalho J, Paula AP et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Rheumatol 2012;52:569–93. - PubMed

LinkOut - more resources